Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18849Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Pappas, G. | en |
| dc.contributor.author | Christou, L. | en |
| dc.contributor.author | Akritidis, N. | en |
| dc.contributor.author | Tsianos, E. V. | en |
| dc.date.accessioned | 2015-11-24T18:55:17Z | - |
| dc.date.available | 2015-11-24T18:55:17Z | - |
| dc.identifier.issn | 1198-743X | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18849 | - |
| dc.rights | Default Licence | - |
| dc.subject | Anti-Infective Agents/pharmacology/*therapeutic use | en |
| dc.subject | Brucella/*drug effects | en |
| dc.subject | Brucellosis/*drug therapy | en |
| dc.subject | Ciprofloxacin/pharmacology/therapeutic use | en |
| dc.subject | Drug Resistance, Bacterial | en |
| dc.subject | Humans | en |
| dc.subject | Quinolones/pharmacology/*therapeutic use | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Quinolones for brucellosis: treating old diseases with new drugs | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1111/j.1469-0691.2006.01442.x | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16882286 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1111/j.1469-0691.2006.01442.x/asset/j.1469-0691.2006.01442.x.pdf?v=1&t=h0p186s6&s=0e7a87d07ea15d0661054381c3c68695fd35db79 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | Although quinolones are theoretically interesting candidates for the treatment of brucellosis, the existing data concerning their efficacy are limited and conflicting. A number of small clinical studies with combination regimens that include quinolones have shown adequacy, but not superiority, although cost-effectiveness, excluding certain disease complications, is an important issue. The emergence of quinolone resistance and its implications is another drawback. Experimental data have yielded contradictory results, although most studies do not indicate a bactericidal effect for quinolones. However, in-vitro studies contrast repeatedly with the clinical response, both in terms of clinical failure, despite in-vitro success, and vice versa. | en |
| heal.journalName | Clin Microbiol Infect | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Pappas-2006-Quinolones for bruce.pdf | 47.41 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
